pharmaphorum

JUNE 23, 2022

The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Our Social Media Platform.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. For more details on this emerging domain, check out the following report : Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

pharmaphorum

OCTOBER 1, 2021

” In its prospectus, Oxford Nanopore said the proceeds from the IPO would be used to increase R&D investment, double its commercial team within the next 18 months, and build up its manufacturing and business development capacity. .” Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Genome Genomics Business Development 52

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. Stéphane Bancel, chief executive officer at Moderna, said: “With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing.”. Biotech Moderna, Inc. The deal marks 10-year-old Moderna’s first acquisition.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

FDA Law Blog

OCTOBER 24, 2024

Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of generic drugs and biosimilar products. The concerns raised by PERA are not limited to these industries, however.

Gene 64

Gene DNA Genetics Gene Sequencing 64